ArticleJAMA health forum2023
State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid Enrollees.
Article in JAMA health forum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 26 citations in OpenAlex.
- "We're All in This Together": A Mixed-Methods Study of Provider and Patient Perceptions of Emergency Care for Opioid Use Disorder.Journal of advanced nursing · 2026Observational
- Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths.JAMA network open · 2026Article
- Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations.Journal of general internal medicine · 2026Article
- Differential associations between social determinants of health and the initiation of medications for opioid use disorder across care settings.npj health systems · 2026Article
- Opioid Use Disorder and Treatment Uptake Among Patients With Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis.Arthritis care & research · 2026Article
- Cascade of Care for Opioid Use Disorder Among Medicaid Beneficiaries.JAMA network open · 2026Article
- Geographic variation in the utilisation of specialist healthcare for patients with substance use disorders in Norway: a population-based registry study.Research in health services & regions · 2026Article
- Spatio-Temporal Modeling for Multi-County Opioid Overdose Surveillance: A Unified Graph Convolutional Framework.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Pharmacotherapy and overdose risk following new opioid use disorder diagnosis among Medicaid beneficiaries.The American journal of drug and alcohol abuse · 2026Article
- Variation in the quality of opioid use disorder treatment in the Medicaid population in 2019.PloS one · 2026Article
- Leveraging pharmacy partnerships and Grant funding to improve access to medications for opioid use disorder.Exploratory research in clinical and social pharmacy · 2025Article
- How Did Medicaid's 1115 Substance Use Disorder Waivers Increase Medication Treatment for Opioid Use Disorder? Evidence From Eight Waiver States.The Milbank quarterly · 2025Article
- Medicaid Primary Care Utilization and Area-Level Social Vulnerability.JAMA health forum · 2025Article
- Hydrocodone Rescheduling and Opioid Prescribing Disparities in Breast Cancer Patients.Cancers · 2025Article
- Benchmarking the Transformed Medicaid Statistical Information System Analytic Files for analysis of opioid use disorder treatment.Health services research · 2025Article
- Detecting Opioid Use Disorder in Health Claims Data With Positive Unlabeled Learning.IEEE journal of biomedical and health informatics · 2025Article
- Receipt of Medications for Alcohol and Opioid Use Disorders: The Importance of Service Utilization Patterns.The journal of behavioral health services & research · 2025Article
- Long-term prescription opioid use following surgery in the US (2017-2022): a population-based study.Lancet regional health. Americas · 2024Article
- Improving access to buprenorphine for rural veterans in a learning health care system.Health services research · 2024Article
- Effects Of Medicaid Waivers On Use Of Medications For Opioid Use Disorder And Nonfatal Overdoses In 17 States.Health affairs (Project Hope) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Importance: The opioid crisis disproportionately affects Medicaid enrollees, yet little systematic evidence exists regarding how prevalence of and health care utilization for opioid use disorder (OUD) vary across geographical areas. Objectives: To characterize state- and county-level variation in claims-based prevalence of OUD and rates of medication treatment for OUD and OUD-related nonfatal overdose among Medicaid enrollees. Design, Setting, and Participants: This cross-sectional study used data from the Transformed Medicaid Statistical Information System Analytic Files from January 1, 2016, to December 31, 2018. Participants were Medicaid enrollees with or without OUD in 46 states; Washington, DC; and Puerto Rico who were aged 18 to 64 years and not dually enrolled in Medicare. The analysis was conducted between September 2022 and April 2023. Exposure: Calendar-year OUD prevalence. Main Outcomes and Measures: The main outcomes were claims-based measures of OUD prevalence and rates of medication treatment for OUD and opioid-related nonfatal overdose. Individual records were aggregated at the state and county level, and variation was assessed within and across states. Results: Of the 76 390 817 Medicaid enrollee-year observations included in our study (mean [SD] enrollee age, 36.5 [1.6] years; 59.0% female), 2 280 272 (3.0%) had a claims-based OUD (mean [SD] age, 38.9 [3.6] years; 51.4% female). Of enrollees with OUD, 41.2% were eligible due to Medicaid expansion, 46.4% had other substance use disorders, 55.8% had mental health conditions, 55.2% had claims indicating some form of OUD medication, and 5.8% had claims indicating an overdose during a calendar year. Claims-based outcomes exhibited substantial variation across states: OUD prevalence ranged from 0.6% in Arkansas and Puerto Rico to 9.7% in Maryland, rates of OUD medication treatment ranged from 17.7% in Kansas to 82.8% in Maine, and rates of overdose ranged from 0.3% in Mississippi to 10.5% in Illinois. Pronounced variation was also found within states (eg, OUD prevalence in Maryland ranged from 2.2% in Prince George's County to 21.6% in Cecil County). Conclusions and Relevance: In this cross-sectional study of Medicaid enrollees from 2016 to 2018, claims-based prevalence of OUD and rates of OUD medication treatment and opioid-related overdose varied substantially across and within states. Further research appears to be needed to identify important factors influencing this variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.